-+ 0.00%
-+ 0.00%
-+ 0.00%

MDB Capital report says retatrutide hits 28.7% weight loss, shifts obesity drug race to IP

PUBT·04/29/2026 15:00:58
Listen to the news
MDB Capital report says retatrutide hits 28.7% weight loss, shifts obesity drug race to IP
  • MDB Capital-backed PatentVest published an industry analysis on obesity drug competition following Eli Lilly retatrutide posting 28.7% mean weight loss in April 2026, matching bariatric outcomes in trials.
  • Report said competitive focus is shifting from clinical efficacy to intellectual-property control, including who can operate around patents or gets blocked from market entry.
  • Analysis cited 27 programs targeting triple-agonist mechanisms, with Novo Nordisk building a multi-asset portfolio while Pfizer entered via acquisition.
  • PatentVest said real-world performance is expected to fall short of trial results, framing adherence and outcomes gap as key battleground for value capture.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MDB Capital Holdings LLC published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604291100PRIMZONEFULLFEED9709559) on April 29, 2026, and is solely responsible for the information contained therein.